Rocket Pharmaceuticals, Inc. (RCKT)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$2.61+3.98%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · RCKT
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -34.8% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name has erratic recent earnings surprises and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
RCKT — credit agreement
Dated 2026-10-06
Entry into a Material Definitive Agreement. Loan and Security Agreement On September 30, 2026, Rocket Pharmaceuticals, Inc. (the “Company”), together with its subsidiaries Spacecraft Seven, LLC and Zebrafish Merger Sub II, LLC (together with the Company, “Borrower”), entered into a Loan and Security Agreement (the “Loan Agreement”) with the several banks and other financial institutions or entities from time to time party thereto (collectively, the “Lenders”) and Hercules Capital, Inc., a Mar…
Why it matters: The first dose would move the BAG3-DCM program from trial start-up into testing in people. A delay would push back that step.
Supportive ifRocket reports that the first patient received RP-A701 in the Phase 1 study during the second half of 2026.
Worry ifRocket reports that no patient has received RP-A701 by the end of 2026, or that the study start is delayed.
Why it matters: The first three patients had no major safety concerns during the set watch period. New safety problems could slow the Danon trial.
Worry ifA company update reports TMA, capillary leak, or another major safety issue. This happened in a patient dosed under the changed Phase 2 plan.
Less concerning ifRocket reports no TMA, capillary leak, or other major safety issue. More patients pass the set watch period.
Why it matters: Rocket is waiting for FDA input after three patients passed the safety watch period. Clear next steps could let the pivotal trial move ahead.
Supportive ifRocket reports FDA agreement to dose more patients. It also reports a clear path to finish the Phase 2 trial in its second-half 2026 update.
Worry ifRocket reports that FDA talks do not resolve the trial path, or that dosing more patients is delayed.
Why it matters: FDA alignment could set the plan for a pivotal PKP2-ACM study. More Phase 1 data could also test the early signs of biological activity.
Supportive ifRocket reports an agreed plan for a possible pivotal study. Phase 1 enrollment continues, with new data on how the treatment affects the body.
Worry ifRocket reports no agreement on the pivotal study plan. Or, Phase 1 enrollment stops, or new data weaken earlier findings.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$270 on $10,000 · ±2.7% | How much price usually moves either way. |
| Bad day | $608 loss on $10,000 · 6.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,887 loss on $10,000 · 58.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: KRESLADI is Rocket's first approved product. Patient starts would show whether its focused launch plan is reaching treatment centers.
Supportive ifRocket reports KRESLADI is for sale. Patient onboarding began in Q4 2026.
Worry ifRocket reports that KRESLADI was not available or patient onboarding did not start in Q4 2026.
Why it matters: Rocket received $35 million and expects cash to last into Q3 2028. More loan funds depend on stated terms and milestones.
Watch forRocket reports cash runway into Q3 2028 or later, with any added loan draw and its conditions stated.
Also watch forRocket reports a runway shorter than Q3 2028, or says it cannot access a planned loan draw under the agreement.